Order Information
Contact us
Insert title here
Featured Products
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10012  |  AZD-5438
HY-10014  |  R547
HY-10032  |  PF 477736
HY-10087  |  Navitoclax
HY-10128  |  ZM-447439
HY-10161  |  Tozasertib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10228  |  Motesanib
HY-10249  |  GSK-690693
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10992  |  AZD-7762
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-11009  |  CGP60474


 (Synonyms  PD325901)
391210-10-9  Technical Data: Price and Availability of  Cas No:391210-10-9

Cas : 391210-10-9 M.Wt: 482.1931
Cas : 391210-10-9 Formula: C16H14F3IN2O4
Cas : 391210-10-9 Purity: >98 %
Cas : 391210-10-9 Storage: at 20℃ 2 years
Cas : 391210-10-9 Solubility: DMSO: ≥ 56 mg/mL
Cas : 391210-10-9 Name: PD0325901
1g/$1400 In-stock
5mg/$50 In-stock
10mg/$90 In-stock
25mg/$150 In-stock
50mg/$190 In-stock
100mg/$290 In-stock
200mg/$470 In-stock
500mg/$940 In-stock
1g Get quote
5g Get quote
>10g Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please
inquire via sales@chemexpress.cn
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Online Inquiry
391210-10-9  Data Sheet:
Introduction of 391210-10-9 :
PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. IC50 & Target: IC50: 0.33 nM (MEK) In Vitro: PF0325901 shows higher permeability, and should be able to achieve higher systemic exposures than CI-1040[1]. PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GC50 of 11 nM and 6.3 nM, respectively. PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines[2].? In Vivo: PD0325901 (25 mg/kg, p.o.) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. The dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. PD0325901 (20-25 mg/kg/day, p.o.) treatment in mice, shows no tumor growth inoculated with PTC cells bearing a BRAF mutation.?For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement[2].
References on 391210-10-9 :

Keywords: buy PD0325901 | PD0325901 Supplier | purchase PD0325901 | PD0325901 cost | PD0325901 manufacturer | order PD0325901 | PD0325901 distributor | PD0325901 structure
buy 391210-10-9 | 391210-10-9 Supplier | purchase 391210-10-9 | 391210-10-9 cost | 391210-10-9 manufacturer | order 391210-10-9 | 391210-10-9 distributor | 391210-10-9 structure
Insert title here
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn